Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Novavax (NVAX) plans to release its third quarter 2026 financial results before U.S. financial markets open on November 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novavax (NVAX) plans to release its third quarter 2026 financial results before U.S. financial markets open on November 5, 2026. Management will then host a webcast and conference call at 8:30 a.m. ET to discuss financial results and operational highlights. A webcast replay will be available approximately two hours after the event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
Conference call details: |
|
|
Date: |
November 5, 2026 |
|
Time: |
8:30 a.m. ET |
|
URL to register phone: |
|
|
Dial-in number: |
(+1) 888-880-3330 ( |
|
Webcast: |
The live webcast can be accessed at ir.novavax.com/events |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
A replay of the webcast will be available at ir.novavax.com/events and over the phone approximately two hours after the event:
|
Replay dial-in number: |
(+1) 800-770-2030 ( |
|
Passcode: |
5780712# |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Naina Zaman
240-410-5353
ir@novavax.com
Media
Yvonne Sprow
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-third-quarter-2026-financial-results-on-november-5-2026-302921398.html
SOURCE Novavax, Inc.